Lineage involvement in 161 NPMc+ AML cases according to FAB criteria
. | . | Lineages Involved* . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| FAB class . | No. of cases . | 1 . | 2 . | More than 2† . | CD34, no. . | ||
| M0-M1 | 21 | 13 My | 5 My + Er; 1 My + Meg | 2 My + Er + Meg | 20 Neg | ||
| M2 | 24 | 13 My | 10 My + Er | 1 My + Er + Meg | 23 Neg | ||
| M4 | 56 | 10 My-Mo | 15 My-Mo + Er; 10 My-Mo + Meg | 21 My-Mo + Meg + Er | 55 Neg | ||
| M5a | 20 | 13 Mo | 1 Mo + Er; 5 Mo + Meg | 1 Mo + Er + Meg | 20 Neg | ||
| M5b | 30 | 12 Mo | 3 M0 + Er; 10 M0 + Meg | 5 M0 + Er + Meg | 30 Neg | ||
| M6 | 10 | 1 Er‡ | 5 Er + My | 4 Er + My + Meg | 10 Neg | ||
| Total, n (%) | 161 | 62 (38.5) | 65 (40.4) | 34 (21.1) | 158 (98.1) | ||
. | . | Lineages Involved* . | . | . | . | ||
|---|---|---|---|---|---|---|---|
| FAB class . | No. of cases . | 1 . | 2 . | More than 2† . | CD34, no. . | ||
| M0-M1 | 21 | 13 My | 5 My + Er; 1 My + Meg | 2 My + Er + Meg | 20 Neg | ||
| M2 | 24 | 13 My | 10 My + Er | 1 My + Er + Meg | 23 Neg | ||
| M4 | 56 | 10 My-Mo | 15 My-Mo + Er; 10 My-Mo + Meg | 21 My-Mo + Meg + Er | 55 Neg | ||
| M5a | 20 | 13 Mo | 1 Mo + Er; 5 Mo + Meg | 1 Mo + Er + Meg | 20 Neg | ||
| M5b | 30 | 12 Mo | 3 M0 + Er; 10 M0 + Meg | 5 M0 + Er + Meg | 30 Neg | ||
| M6 | 10 | 1 Er‡ | 5 Er + My | 4 Er + My + Meg | 10 Neg | ||
| Total, n (%) | 161 | 62 (38.5) | 65 (40.4) | 34 (21.1) | 158 (98.1) | ||
My indicates myeloid; Mo, monocytic; My-Mo, myelo-monocytic; Er, erythroid; Meg, megakaryocytic.
Assessed by detection of cytoplasmic NPM with antibodies (clones 322 and 376) recognizing both the wild-type and mutated NPM proteins.
Involvement of erythroid precursors was confirmed by double staining glycophorin A/NPM in all cases and by labeling with Sil-A antibody in cases where antigenicity was preserved.
Refers to the only case of M6b in this series.